The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Bladder Cancer Therapeutics and Diagnostics-Global Market Insights and Sales Trends 2024
Synopsis
The bladder is an organ located in the lower abdominal region near the pelvic bones and acts as a reservoir of urine. A bladder cancer is characterized by the abnormal cell growth in the bladder, which impairs the proper functioning of urinary system. Majority of bladder cancer develops in the innermost layer called urothelium or transitional epithelium, composed of epithelium or transitional cells.
The global Bladder Cancer Therapeutics and Diagnostics market size is expected to reach US$ 710.7 million by 2029, growing at a CAGR of 6.9% from 2023 to 2029. The market is mainly driven by the significant applications of Bladder Cancer Therapeutics and Diagnostics in various end use industries. The expanding demands from the Hospitals, Oncology Treatment Centers, Ambulatory Surgery Centers and Others, are propelling Bladder Cancer Therapeutics and Diagnostics market. Chemotherapy, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Immunotherapy segment is estimated at % CAGR for the next seven-year period.
Based on the data from International Agency for Research on Cancer, bladder cancer is the 6th most commonly diagnosed cancer of males and the 9th leading cause of cancer deaths worldwide. Historically, bladder cancer has been associated with low patient awareness. Smoking has a high correlation with bladder cancer and this association is mostly unknown to the general public. But, in recent years, the awareness regarding bladder diseases and their management has drastically improved, particularly in developed nations.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Bladder Cancer Therapeutics and Diagnostics, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Bladder Cancer Therapeutics and Diagnostics market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Bladder Cancer Therapeutics and Diagnostics market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Bladder Cancer Therapeutics and Diagnostics sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Bladder Cancer Therapeutics and Diagnostics covered in this report include Pfizer, GlaxoSmithKline, Merck, Novartis, Bristol-Myers Squibb, Eli Lilly, Roche, Sanofi and AstraZeneca, etc.
The global Bladder Cancer Therapeutics and Diagnostics market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Pfizer
GlaxoSmithKline
Merck
Novartis
Bristol-Myers Squibb
Eli Lilly
Roche
Sanofi
AstraZeneca
Celgene Corporation
Global Bladder Cancer Therapeutics and Diagnostics market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Bladder Cancer Therapeutics and Diagnostics market, Segment by Type:
Chemotherapy
Immunotherapy
Radiation Therapy
Others
Global Bladder Cancer Therapeutics and Diagnostics market, by Application
Hospitals
Oncology Treatment Centers
Ambulatory Surgery Centers
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Bladder Cancer Therapeutics and Diagnostics companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
The bladder is an organ located in the lower abdominal region near the pelvic bones and acts as a reservoir of urine. A bladder cancer is characterized by the abnormal cell growth in the bladder, which impairs the proper functioning of urinary system. Majority of bladder cancer develops in the innermost layer called urothelium or transitional epithelium, composed of epithelium or transitional cells.
The global Bladder Cancer Therapeutics and Diagnostics market size is expected to reach US$ 710.7 million by 2029, growing at a CAGR of 6.9% from 2023 to 2029. The market is mainly driven by the significant applications of Bladder Cancer Therapeutics and Diagnostics in various end use industries. The expanding demands from the Hospitals, Oncology Treatment Centers, Ambulatory Surgery Centers and Others, are propelling Bladder Cancer Therapeutics and Diagnostics market. Chemotherapy, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Immunotherapy segment is estimated at % CAGR for the next seven-year period.
Based on the data from International Agency for Research on Cancer, bladder cancer is the 6th most commonly diagnosed cancer of males and the 9th leading cause of cancer deaths worldwide. Historically, bladder cancer has been associated with low patient awareness. Smoking has a high correlation with bladder cancer and this association is mostly unknown to the general public. But, in recent years, the awareness regarding bladder diseases and their management has drastically improved, particularly in developed nations.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Bladder Cancer Therapeutics and Diagnostics, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Bladder Cancer Therapeutics and Diagnostics market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Bladder Cancer Therapeutics and Diagnostics market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Bladder Cancer Therapeutics and Diagnostics sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Bladder Cancer Therapeutics and Diagnostics covered in this report include Pfizer, GlaxoSmithKline, Merck, Novartis, Bristol-Myers Squibb, Eli Lilly, Roche, Sanofi and AstraZeneca, etc.
The global Bladder Cancer Therapeutics and Diagnostics market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Pfizer
GlaxoSmithKline
Merck
Novartis
Bristol-Myers Squibb
Eli Lilly
Roche
Sanofi
AstraZeneca
Celgene Corporation
Global Bladder Cancer Therapeutics and Diagnostics market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Bladder Cancer Therapeutics and Diagnostics market, Segment by Type:
Chemotherapy
Immunotherapy
Radiation Therapy
Others
Global Bladder Cancer Therapeutics and Diagnostics market, by Application
Hospitals
Oncology Treatment Centers
Ambulatory Surgery Centers
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Bladder Cancer Therapeutics and Diagnostics companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Bladder Cancer Therapeutics and Diagnostics
1.1 Bladder Cancer Therapeutics and Diagnostics Market Overview
1.1.1 Bladder Cancer Therapeutics and Diagnostics Product Scope
1.1.2 Bladder Cancer Therapeutics and Diagnostics Market Status and Outlook
1.2 Global Bladder Cancer Therapeutics and Diagnostics Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Bladder Cancer Therapeutics and Diagnostics Market Size by Region (2018-2029)
1.4 Global Bladder Cancer Therapeutics and Diagnostics Historic Market Size by Region (2018-2023)
1.5 Global Bladder Cancer Therapeutics and Diagnostics Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Bladder Cancer Therapeutics and Diagnostics Market Size (2018-2029)
1.6.1 North America Bladder Cancer Therapeutics and Diagnostics Market Size (2018-2029)
1.6.2 Europe Bladder Cancer Therapeutics and Diagnostics Market Size (2018-2029)
1.6.3 Asia-Pacific Bladder Cancer Therapeutics and Diagnostics Market Size (2018-2029)
1.6.4 Latin America Bladder Cancer Therapeutics and Diagnostics Market Size (2018-2029)
1.6.5 Middle East & Africa Bladder Cancer Therapeutics and Diagnostics Market Size (2018-2029)
2 Bladder Cancer Therapeutics and Diagnostics Market by Type
2.1 Introduction
2.1.1 Chemotherapy
2.1.2 Immunotherapy
2.1.3 Radiation Therapy
2.1.4 Others
2.2 Global Bladder Cancer Therapeutics and Diagnostics Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Bladder Cancer Therapeutics and Diagnostics Historic Market Size by Type (2018-2023)
2.2.2 Global Bladder Cancer Therapeutics and Diagnostics Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Bladder Cancer Therapeutics and Diagnostics Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Bladder Cancer Therapeutics and Diagnostics Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Bladder Cancer Therapeutics and Diagnostics Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Bladder Cancer Therapeutics and Diagnostics Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Bladder Cancer Therapeutics and Diagnostics Revenue Breakdown by Type (2018-2029)
3 Bladder Cancer Therapeutics and Diagnostics Market Overview by Application
3.1 Introduction
3.1.1 Hospitals
3.1.2 Oncology Treatment Centers
3.1.3 Ambulatory Surgery Centers
3.1.4 Others
3.2 Global Bladder Cancer Therapeutics and Diagnostics Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Bladder Cancer Therapeutics and Diagnostics Historic Market Size by Application (2018-2023)
3.2.2 Global Bladder Cancer Therapeutics and Diagnostics Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Bladder Cancer Therapeutics and Diagnostics Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Bladder Cancer Therapeutics and Diagnostics Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Bladder Cancer Therapeutics and Diagnostics Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Bladder Cancer Therapeutics and Diagnostics Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Bladder Cancer Therapeutics and Diagnostics Revenue Breakdown by Application (2018-2029)
4 Bladder Cancer Therapeutics and Diagnostics Competition Analysis by Players
4.1 Global Bladder Cancer Therapeutics and Diagnostics Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Bladder Cancer Therapeutics and Diagnostics as of 2022)
4.3 Date of Key Players Enter into Bladder Cancer Therapeutics and Diagnostics Market
4.4 Global Top Players Bladder Cancer Therapeutics and Diagnostics Headquarters and Area Served
4.5 Key Players Bladder Cancer Therapeutics and Diagnostics Product Solution and Service
4.6 Competitive Status
4.6.1 Bladder Cancer Therapeutics and Diagnostics Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Pfizer
5.1.1 Pfizer Profile
5.1.2 Pfizer Main Business
5.1.3 Pfizer Bladder Cancer Therapeutics and Diagnostics Products, Services and Solutions
5.1.4 Pfizer Bladder Cancer Therapeutics and Diagnostics Revenue (US$ Million) & (2018-2023)
5.1.5 Pfizer Recent Developments
5.2 GlaxoSmithKline
5.2.1 GlaxoSmithKline Profile
5.2.2 GlaxoSmithKline Main Business
5.2.3 GlaxoSmithKline Bladder Cancer Therapeutics and Diagnostics Products, Services and Solutions
5.2.4 GlaxoSmithKline Bladder Cancer Therapeutics and Diagnostics Revenue (US$ Million) & (2018-2023)
5.2.5 GlaxoSmithKline Recent Developments
5.3 Merck
5.3.1 Merck Profile
5.3.2 Merck Main Business
5.3.3 Merck Bladder Cancer Therapeutics and Diagnostics Products, Services and Solutions
5.3.4 Merck Bladder Cancer Therapeutics and Diagnostics Revenue (US$ Million) & (2018-2023)
5.3.5 Novartis Recent Developments
5.4 Novartis
5.4.1 Novartis Profile
5.4.2 Novartis Main Business
5.4.3 Novartis Bladder Cancer Therapeutics and Diagnostics Products, Services and Solutions
5.4.4 Novartis Bladder Cancer Therapeutics and Diagnostics Revenue (US$ Million) & (2018-2023)
5.4.5 Novartis Recent Developments
5.5 Bristol-Myers Squibb
5.5.1 Bristol-Myers Squibb Profile
5.5.2 Bristol-Myers Squibb Main Business
5.5.3 Bristol-Myers Squibb Bladder Cancer Therapeutics and Diagnostics Products, Services and Solutions
5.5.4 Bristol-Myers Squibb Bladder Cancer Therapeutics and Diagnostics Revenue (US$ Million) & (2018-2023)
5.5.5 Bristol-Myers Squibb Recent Developments
5.6 Eli Lilly
5.6.1 Eli Lilly Profile
5.6.2 Eli Lilly Main Business
5.6.3 Eli Lilly Bladder Cancer Therapeutics and Diagnostics Products, Services and Solutions
5.6.4 Eli Lilly Bladder Cancer Therapeutics and Diagnostics Revenue (US$ Million) & (2018-2023)
5.6.5 Eli Lilly Recent Developments
5.7 Roche
5.7.1 Roche Profile
5.7.2 Roche Main Business
5.7.3 Roche Bladder Cancer Therapeutics and Diagnostics Products, Services and Solutions
5.7.4 Roche Bladder Cancer Therapeutics and Diagnostics Revenue (US$ Million) & (2018-2023)
5.7.5 Roche Recent Developments
5.8 Sanofi
5.8.1 Sanofi Profile
5.8.2 Sanofi Main Business
5.8.3 Sanofi Bladder Cancer Therapeutics and Diagnostics Products, Services and Solutions
5.8.4 Sanofi Bladder Cancer Therapeutics and Diagnostics Revenue (US$ Million) & (2018-2023)
5.8.5 Sanofi Recent Developments
5.9 AstraZeneca
5.9.1 AstraZeneca Profile
5.9.2 AstraZeneca Main Business
5.9.3 AstraZeneca Bladder Cancer Therapeutics and Diagnostics Products, Services and Solutions
5.9.4 AstraZeneca Bladder Cancer Therapeutics and Diagnostics Revenue (US$ Million) & (2018-2023)
5.9.5 AstraZeneca Recent Developments
5.10 Celgene Corporation
5.10.1 Celgene Corporation Profile
5.10.2 Celgene Corporation Main Business
5.10.3 Celgene Corporation Bladder Cancer Therapeutics and Diagnostics Products, Services and Solutions
5.10.4 Celgene Corporation Bladder Cancer Therapeutics and Diagnostics Revenue (US$ Million) & (2018-2023)
5.10.5 Celgene Corporation Recent Developments
6 North America
6.1 North America Bladder Cancer Therapeutics and Diagnostics Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Bladder Cancer Therapeutics and Diagnostics Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Bladder Cancer Therapeutics and Diagnostics Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Bladder Cancer Therapeutics and Diagnostics Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Bladder Cancer Therapeutics and Diagnostics Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Bladder Cancer Therapeutics and Diagnostics Market Dynamics
11.1 Bladder Cancer Therapeutics and Diagnostics Industry Trends
11.2 Bladder Cancer Therapeutics and Diagnostics Market Drivers
11.3 Bladder Cancer Therapeutics and Diagnostics Market Challenges
11.4 Bladder Cancer Therapeutics and Diagnostics Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
